Hawryluk P. Kent 4
4 · MBX Biosciences, Inc. · Filed Feb 27, 2026
Research Summary
AI-generated summary of this filing
MBX Biosciences CEO P. Kent Hawryluk Exercises Options for 28,768 Shares
What Happened
P. Kent Hawryluk, President & CEO and a director of MBX Biosciences (MBX), exercised stock options on 2026-02-26 to acquire 28,768 shares at a $16.00 exercise price, for a total cash outlay of $460,288. The filing also reports the corresponding derivative (the option) as disposed (converted) at $0 in connection with the exercise. No shares were reported sold as part of this transaction.
Key Details
- Transaction date: 2026-02-26; Form 4 filed 2026-02-27 (timely).
- Shares acquired: 28,768 common shares at $16.00 each; total = $460,288.
- Derivative: the option underlying these shares was reported disposed/converted (code M).
- Shares owned after transaction: not specified in the provided data.
- Footnote F1: Some shares are held by the P. Kent Hawryluk Revocable Trust (he is trustee and disclaims beneficial ownership except for pecuniary interest).
- Footnote F2: Vesting: 25% of the option vested on Sept 12, 2025; remaining 75% vests in 36 equal monthly installments, contingent on continued service.
Context
This was an exercise of previously granted options (transaction code M) rather than an open-market purchase or sale. Because no sale was reported at exercise, this was not a cashless exercise—Hawryluk paid the $16 strike price to receive the shares. Exercises like this increase an insider’s raw share count but are not in themselves a direct signal of buying or selling intent.
Insider Transaction Report
- Exercise/Conversion
Common Stock
2026-02-26$16.00/sh+28,768$460,288→ 728,274 total - Exercise/Conversion
Stock option (right to buy)
[F2]2026-02-26−28,768→ 91,668 totalExercise: $16.00Exp: 2034-09-12→ Common Stock (28,768 underlying)
- 468,277(indirect: By Trust)
Common Stock
[F1]
Footnotes (2)
- [F1]Shares held by the P. Kent Hawryluk Revocable Trust dated January 25, 2011, of which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose.
- [F2]25% of the shares underlying this option vested and became exercisable on September 12, 2025, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.